Synchron Secures $200 Million to Advance Stentrode Platform Commercialisation
Synchron has raised $200 million in a Series D funding round to accelerate the commercial launch of its Stentrode brain-computer interface (BCI) platform and support the development of next-generation interfaces.
Funding Details and Investors
The investment round was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI.
- New investors joining this round include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Use of Funds and Clinical Progress
Synchron plans to use the funding to speed up critical clinical studies and expand its multidisciplinary team.
CEO Statement on Stentrode Development
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
— Tom Oxley, Founder and CEO of Synchron
Industry Impact
Synchron aims to lead in brain-computer interface technology by commercialising a device that integrates seamlessly into daily life, potentially transforming treatment options for paralysis.
Additional Notes
Stentrode represents significant progress in non-surgical neural interfaces, emphasizing patient accessibility and next-level connectivity through innovative design and clinical validation.
Author’s summary: Synchron’s $200 million funding propels the commercialisation of its groundbreaking non-surgical brain-computer interface, advancing next-generation neural technology for paralysis treatment.